SCHEMBL433807

SCHEMBL433807

COc1cccc(-c2c3nc(c(-c4cccc(OC)c4)c4ccc([nH]4)c(-c4cccc(OC)c4)c4nc(c(-c5cccc(OC)c5)c5ccc2[nH]5)C=C4)C=C3)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TERT O14746 4/20 0.49
▸ AURKA O14965 1/20 0.47
▸ KDM4E B2RXH2 1/20 0.47
▸ MEN1 O00255 1/20 0.47
▸ NPC1 O15118 1/20 0.47
▸ MAPT P10636 1/20 0.47
▸ RAB9A P51151 1/20 0.47
▸ KMT2A Q03164 1/20 0.47
▸ NR1I2 O75469 1/20 0.46
▸ CYP1A2 P05177 1/20 0.46
▸ VDR P11473 1/20 0.46
▸ CYP2C9 P11712 1/20 0.46
▸ CYP2B6 P20813 1/20 0.46
▸ AHR P35869 1/20 0.46
▸ NR1I3 Q14994 1/20 0.46
▸ DYRK1A Q13627 1/20 0.45
▸ CLK4 Q9HAZ1 1/20 0.45
▸ ABCG2 Q9UNQ0 1/20 0.45
▸ MAPK13 O15264 1/20 0.44
▸ RAF1 P04049 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30081962 1.00 TERT (0.49) TERTAURKAKDM4EMEN1NPC1
SCHEMBL17687648 0.92 TERT (0.43) TERTAURKAKDM4EMEN1NPC1
SCHEMBL14703823 0.90 ADORA2A (0.43) TERTMEN1KMT2AABCG2MAPK13
SCHEMBL14703874 0.89 TERT (0.41) TERTAURKAKDM4EMEN1NPC1
SCHEMBL17687652 0.87 STAT3 (0.57) TERTAURKAKDM4EMEN1NPC1
SCHEMBL14285083 0.87 NR1I2 (0.40) TERTAURKAKDM4EMEN1NPC1
SCHEMBL498495 0.86 TERT (0.51) TERTKDM4EMEN1MAPTKMT2A
SCHEMBL29408468 0.86 TERT (0.51) TERTKDM4EMEN1MAPTKMT2A
SCHEMBL585528 0.85 STAT3 (0.62) AURKAKDM4EMEN1NPC1MAPT
SCHEMBL31055740 0.85 STAT3 (0.62) AURKAKDM4EMEN1NPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9867800-B2 Method of quenching singlet and triplet excited states of pigments, such as porphyrin compounds, particularly protoporphyrin IX, with conjugated fused tricyclic compounds have electron withdrawing groups, to reduce generation of reactive oxygen species, particularly singlet oxygen HALLSTAR INNOVATIONS CORP. (US) 2018-01-16 — — US claimed
US-20150164852-A1 METHOD OF QUENCHING SINGLET AND TRIPLET EXCITED STATES OF PIGMENTS, SUCH AS PORPHYRIN COMPOUNDS, PARTICULARLY PROTOPORPHYRIN IX, WITH CONJUGATED FUSED TRICYCLIC COMPOUNDS HAVE ELECTRON WITHDRAWING GROUPS, TO REDUCE GENERATION OF REACTIVE OXYGEN SPECIES, PARTICULARLY SINGLET OXYGEN HALLSTAR INNOVATIONS CORP. (US) 2015-06-18 — — US claimed
WO-2014025370-A1 TRICYCLIC ENERGY QUENCHER COMPOUNDS FOR REDUCING SINGLET OXYGEN GENERATION HALLSTAR INNOVATIONS CORP. (US) 2014-02-13 — — WO claimed
US-4746735-A NITRATING AGENT, SOLVENT, SMALL AMOUNT OF SULFURIC ACID CATALYST THE DOW CHEMICAL COMPANY (US) 1988-05-24 — — US claimed
US-12071498-B2 Radically polymerizable compositions Polynt Composites USA, Inc. (US) 2024-08-27 — — US disclosed
CN-113474383-B Free radical polymerizable composition 波林复合材料美国股份有限公司 2023-10-31 — — CN disclosed
US-20230257500-A1 RADICALLY POLYMERIZABLE COMPOSITIONS BNY MELLON CORPORATE TRUSTEE SERVICES LIMITED, AS SECURITY AGENT (GB) 2023-08-17 — — US disclosed
US-11518834-B2 Radically polymerizable compositions Polynt Composites USA, Inc. (US) 2022-12-06 — — US disclosed
EP-3077467-B1 DRIER COMPOSITION AND USE THEREOF PPG EUROPE B V (NL) 2022-11-02 — — EP disclosed
EP-3906265-A1 RADICALLY POLYMERIZABLE COMPOSITIONS Polynt Composites USA Inc. (US) 2021-11-10 — — EP disclosed
CN-113474383-A Radically polymerizable composition 波林复合材料美国股份有限公司 2021-10-01 — — CN disclosed
EP-2379109-B1 COMBINATION OF PHOTODYNAMIC THERAPY AND ANTI-VEGF AGENTS IN THE TREATMENT OF UNWANTED CHOROIDAL NEOVASCULATURE BAUSCH HEALTH COMPANIES INC (CA) 2020-10-07 — — EP disclosed
WO-2003028628-A2 PHOTOSENSITIZING CARBAMATE DERIVATIVES MIRAVANT PHARMACEUTICALS, INC. (US) 2003-04-10 — — WO disclosed
US-20020183302-A1 Method to prevent vision loss TECHNOLAS PERFECT VISION GMBH (DE) 2002-12-05 — — US disclosed
US-20020173832-A1 Reduced fluence rate PDT TECHNOLAS PERFECT VISION GMBH (DE) 2002-11-21 — — US disclosed
US-20020155089-A1 Drug delivery systems for photodynamic therapy UNIVERSITY OF BRITISH COLUMBIA, THE (CA) 2002-10-24 — — US disclosed
US-20020156062-A1 Drug delivery system for hydrophobic drugs BAUSCH HEALTH COMPANIES INC. (CA) 2002-10-24 — — US disclosed
US-20020061330-A1 Supports for photosensitizer formulations BRITISH COLUMBIA, THE UNIVERSITY OF (CA) 2002-05-23 — — US disclosed
US-20020022032-A1 Immuno-adjuvant PDT treatment of metastatic tumors QLT INC. (CA) 2002-02-21 — — US disclosed
US-4746735-A NITRATING AGENT, SOLVENT, SMALL AMOUNT OF SULFURIC ACID CATALYST THE DOW CHEMICAL COMPANY (US) 1988-05-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020183302-A1 Method to prevent vision loss VEGFA, ALDH1A2, PDE6C TERT 2302/4885AURKA 4774/4885KDM4E 3259/4885
US-20020156062-A1 Drug delivery system for hydrophobic drugs LIPA, MLEC, ABCG2 TERT 4251/4885AURKA 2041/4885KDM4E 3305/4885
US-20020155089-A1 Drug delivery systems for photodynamic therapy PIN1, PPOX, DHFR TERT 3224/4885AURKA 958/4885KDM4E 1989/4885
US-20020061330-A1 Supports for photosensitizer formulations PPOX, PPIF, SDHA TERT 2853/4885AURKA 2544/4885KDM4E 3097/4885
US-20150164852-A1 METHOD OF QUENCHING SINGLET AND TRIPLET EXCITED STATES OF PIGMENTS, SUCH AS PORPHYRIN COMPOUNDS, PARTICULARLY PROTOPORPHYRIN IX, WITH CONJUGATED FUSED TRICYCLIC COMPOUNDS HAVE ELECTRON WITHDRAWING GROUPS, TO REDUCE GENERATION OF REACTIVE OXYGEN SPECIES, PARTICULARLY SINGLET OXYGEN NOX3, CBR3, CCR3 TERT 1768/4885AURKA 4496/4885KDM4E 4828/4885
US-20020022032-A1 Immuno-adjuvant PDT treatment of metastatic tumors CD74, ANXA11, ANXA1 TERT 2006/4885AURKA 1900/4885KDM4E 4361/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback